Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13001607 | 1.00 | NAMPT (0.38) | NAMPTTNKS2NSD2HPGDEPHX1 | |
| SCHEMBL2994943 | 0.88 | TNKS2 (0.42) | NAMPTTNKS2HPGDEPHX1KMT2A | |
| SCHEMBL15443047 | 0.84 | — | — | |
| SCHEMBL21896864 | 0.81 | NAMPT (0.41) | NAMPTTNKS2NSD2HPGDCTSD | |
| SCHEMBL2038811 | 0.81 | HPGD (0.36) | NAMPTNSD2HPGDKMT2AALDH1A1 | |
| SCHEMBL12488969 | 0.81 | NAMPT (0.38) | NAMPTTNKS2NSD2HPGDEPHX1 | |
| SCHEMBL15429706 | 0.80 | CTSD (0.37) | NAMPTTNKS2NSD2HPGDEPHX1 | |
| SCHEMBL16790679 | 0.78 | — | — | |
| SCHEMBL13616894 | 0.78 | — | — | |
| SCHEMBL18083628 | 0.77 | BRD4 (0.41) | NAMPTBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109698-A1 | MALT-1 MODULATORS | EXSCIENTIA AI LIMITED (GB) | 2026-04-23 | — | — | US | disclosed |
| US-20250051327-A1 | MALT-1 MODULATORS | RECURSION PHARMACEUTICALS, INC. | 2025-02-13 | — | — | US | disclosed |
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3284741-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9156823-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | Gelead Sciences, Inc. | 2014-01-16 | — | — | US | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NAMPT 663/4885TNKS2 877/4885NSD2 1045/4885 |
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | NAMPT 3641/4885TNKS2 356/4885NSD2 1214/4885 |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NAMPT 663/4885TNKS2 877/4885NSD2 1045/4885 |
| US-20250051327-A1 | MALT-1 MODULATORS | MALT1, BCL6, BCL9 | NAMPT 2608/4885TNKS2 2334/4885NSD2 2996/4885 |
| US-20260109698-A1 | MALT-1 MODULATORS | MALT1, BCL6, BCL3 | NAMPT 4751/4885TNKS2 4527/4885NSD2 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.